Market Cap$63.3m

Last Close $0.25

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and ClyraGuard, a disinfectant for healthcare workers. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

More BioLargo content >

Investment summary

BioLargo reported $666,000 in total Q320 sales (+24.7% y-o-y), a new record, a $1.9m operating loss (flat year-on-year) and a $2.39m net loss (from $3.89m in Q319). It had $356,000 in Q320 sales from ONM Environmental, down 10% from Q319, but the division recovered significantly since the start of the pandemic (up 19% from Q120). Sequentially, companywide revenue growth was up 56% over Q220, a strong bounce back from COVID-19 disruptions, and total sales are up 15% for 9M20 to $1.52m. BioLargo also announced that BioLargo Water is ready for commercial operations and we expect to see an increased sales effort.

Content on BioLargo
BioLargo – Firing on all cylinders
Healthcare | QuickView | 17 December 2020
BioLargo – Clyraguard to be a major growth driver
Healthcare | QuickView | 27 August 2020
BioLargo – Clyra launches Clyraguard
Healthcare | QuickView | 26 May 2020
View more
Register to receive research on BioLargo as it is published
Share price graph
Price performance
Actual 24.3 41.9 61.3
Relative* 26.6 43.6 38.6
52-week high/low US$0.2/US$0.1
*% relative to local index
Key management
Dennis Calvert President & CEO